Shaobin Yang

Dr. Shaobin Yang


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YCYanfen Cui
Yanfen Cui
SYShaobin Yang
Shaobin Yang
XFXin Fu
Xin Fu
JFJingwen Feng
Jingwen Feng
SXShilei Xu
Shilei Xu
GYGuoguang Ying
Guoguang Ying
KAP1 is an universal corepressor for Kruppel-associated box zinc finger proteins in both normal and tumor cells. In this study, the biological function and clinical significance of KAP1 expression in ovarian cancer were investigated. Immunohistological staining of KAP1 was evaluated in 111 patients with ovarian epithelial cancer, 15 with ovarian borderline tumor, and 20 normal ovarian tissue. The correlations of KAP1 expression with clinicopathological features were studied. Kaplan-Meier analysis and Cox proportional hazard modeling were used to assess overall survival to analyze the effect of KAP1 expression on the prognosis of ovarian cancer. The positive rates of KAP1 were significantly higher in ovarian epithelial cancer (55.7%) and borderline tumor (20.0%) than in normal ovarian tissue (5.0%) (all p < 0.01). KAP1 expression correlated significantly with clinical stage (χ2 = 14.57, p < 0.0001), pathological grade (χ2 = 6.06, p = 0.048) and metastases (χ2 =10.38, p = 0.001). Patients with high KAP 1 levels showed poor survival (p < 0.0001). Multivariate analysis showed that KAP1 high expression was an independent predictor for ovarian cancer patients (hazard ratio = 0.463; 95% confidence interval = 0.230–0.9318, p = 0.031). Functionally, depletion of KAP1 by siRNA inhibited ovarian cancer cell proliferation, cell migration. KAP1 expression correlated with aggressive clinical features in ovarian cancer. High KAP1 expression was a prognostic factor of ovarian cancer.

22 July 2024 in Neuropharmacology
Verified
Journal Article
Closed access
SYShaobin Yang
Shaobin Yang
QTQi Tang
Qi Tang
YZYimeng Zhang
Yimeng Zhang
YDYaqin Du
Yaqin Du
XZXiaoqian Zhao
Xiaoqian Zhao
YLYanhong Li
Yanhong Li

1 August 2022 in Blood Science
Verified
Journal Article
Open access
YZYanqing Zhang
Yanqing Zhang
HBHailiang Bi
Hailiang Bi
YWYing Wang
Ying Wang
LCLong Chen
Long Chen
JPJiaqi Pan
Jiaqi Pan
SYShaobin Yang
Shaobin Yang
Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case of a patient with JAK2 V617F- positive ET who subsequently acquired BCR–ABL1, which transformed the disease into CML after 10 years from the initial diagnosis. In this study, we dynamically monitored JAK2 V617F and BCR-ABL and observed multiple gene mutations, including IDH2, IDH1, ASXL1, KRAS, and RUNX1. It is important to be aware of this potentially clone evolution in disease progression.

6 March 2024 in Cancer Genetics
Verified
Journal Article
Closed access
BHBingbing Han
Bingbing Han
YJYu Jing
Yu Jing
XBXiaoyu Bi
Xiaoyu Bi
YLYani Lin
Yani Lin
HLHuilan Li
Huilan Li
SYShaobin Yang
Shaobin Yang

16 March 2024 in Journal of Hematopathology
Verified
Journal Article
Closed access
PDF file
XBXiaoyu Bi
Xiaoyu Bi
CLChao Li
Chao Li
MSMiao Shang
Miao Shang
BHBingbing Han
Bingbing Han
HLHongyu Li
Hongyu Li
SYShaobin Yang
Shaobin Yang

22 December 2025 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
DGDongmei Guo
Dongmei Guo
CWCui Wang
Cui Wang
JYJingya Yao
Jingya Yao
LCLong Chen
Long Chen
YNYanbo Nie
Yanbo Nie
YLYani Lin
Yani Lin
The t(16;21)(q24;q22) translocation creates the RUNX1::RUNX1T3 (also known as CBFA2T3, MTG16) fusion gene, representing a rare but clinically significant subtype of myeloid neoplasms. This comprehensive study presents detailed clinical, immunophenotypic, cytogenetic, and molecular data from 10 new cases while integrating findings from 35 previously reported cases. Patients showed a median age of 48 years with notable female predominance. Immunophenotypic analysis consistently demonstrated a distinctive hybrid myeloid/B-lymphoid phenotype characterized by CD19 co-expression with myeloid markers. Cytogenetic evaluation revealed additional chromosomal abnormalities in 75.6% of cases, with trisomy 8 being most frequent (42.2%). Next-generation sequencing identified recurrent mutations in ASXL1 (50%), TET2, JAK2, and NRAS (each 25%). Clinically, this fusion strongly correlated with therapy-related myeloid neoplasms and demonstrated significantly worse survival outcomes compared to RUNX1::RUNX1T1 AML, highlighting its distinct clinicopathological features and adverse prognostic implications.